ArticleJournal of global health2026
The effect of diagnosis-related group policy on treatment cost and treatment efficiency of inpatients with coronary heart disease in Xinjiang: an interrupted time series analysis.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The high incidence and economic burden of coronary heart disease (CHD) represent a major public health challenge in Xinjiang, a region in northwest China. We aimed to assess the effects of a diagnosis-related group (DRG) policy on treatment costs and treatment efficiency in Bortala Mongol Autonomous Prefecture, Kashgar, and Kizilsu Kirghiz Autonomous Prefecture of Xinjiang, China. Methods: We retrieved data on CHD inpatients from three prefectures in the Xinjiang medical insurance database. Then, we used interrupted time series analyses to evaluate the effect of the DRG policy on these inpatients. The analysis spanned the period from 1 January 2022 to 31 December 2024, with the policy intervention point for each prefecture defined by its respective DRG implementation date. We divided patients into pre-DRG and post-DRG groups based on the timing of the DRG policy's implementation. The outcome variables for treatment costs were total cost, drug cost, medical supplies cost, and out-of-pocket (OOP) payments; the outcome variable for treatment efficiency was length of stay (LOS). Results: Compared to the pre-DRG period, the total cost, drug cost, OOP, and LOS for CHD inpatients in three prefectures all decreased, with a growth rate (GR)<0. In contrast, the medical supplies cost in the Bortala Mongol Autonomous Prefecture and the Kizilsu Kirghiz Autonomous Prefecture increased (GR>0). Following the implementation of the DRG in Xinjiang, CHD inpatients in the Bortala Mongol Autonomous Prefecture saw a significant downward trend in drug cost (β Conclusions: The DRG policy in Xinjiang has successfully controlled certain treatment costs and improved treatment efficiency for inpatients with CHD in the Bortala Mongol Autonomous Prefecture and in Kashgar. However, the implementation of DRG in the Kizilsu Kirghiz Autonomous Prefecture has not yet shown significant results and thus warrants monitoring and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.